Paper41814014
Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
Loghavi S and 24 others. Leukemia, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Immunophenotypic changes following menin inhibition in acute myeloid leukemia. Papers, record 41814014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41814014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Proto-Oncogene Proteins | Major topic |
| Humans | |
| Immunophenotyping | |
| Nucleophosmin | |
| Female | |
| Middle Aged | |
| Male | |
| Aged | |
| Adult | |
| Neoplasm, Residual | |
| Flow Cytometry | |
| Prognosis | |
| Aged, 80 and over | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Faculty Scholar Award | UT | University of Texas MD Anderson Cancer Center (MD Anderson) | PubMed |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 2 | 11113197 | Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. | Mol Cell Biol | 2001 | https://conductscience.org/library/papers/11113197 | PubMed |
| 3 | 34724563 | 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. | Blood | 2021 | https://conductscience.org/library/papers/34724563 | PubMed |
| 4 | 30803991 | Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. | Blood | 2019 | https://conductscience.org/library/papers/30803991 | PubMed |
| 5 | 30171025 | Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. | Haematologica | 2019 | https://conductscience.org/library/papers/30171025 | PubMed |
| 6 | 35618837 | A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. | Nat Med | 2022 | https://conductscience.org/library/papers/35618837 | PubMed |
| 7 | 29128069 | How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? | Clin Lab Med | 2017 | https://conductscience.org/library/papers/29128069 | PubMed |
| 8 | 25817203 | Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25817203 | PubMed |
| 9 | 39362248 | Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/39362248 | PubMed |
| 10 | 32001657 | Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. | Science | 2020 | https://conductscience.org/library/papers/32001657 | PubMed |
| 11 | 40409258 | Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. | Cell Stem Cell | 2025 | https://conductscience.org/library/papers/40409258 | PubMed |
| 12 | 31821784 | A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. | Cancer Cell | 2019 | https://conductscience.org/library/papers/31821784 | PubMed |
| 13 | 40522873 | Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort. | Arch Pathol Lab Med | 2025 | https://conductscience.org/library/papers/40522873 | PubMed |
| 14 | 37605812 | Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. | Cytometry B Clin Cytom | 2023 | https://conductscience.org/library/papers/37605812 | PubMed |
| 15 | 31974170 | Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. | Cancer Discov | 2020 | https://conductscience.org/library/papers/31974170 | PubMed |
| 16 | 33618432 | Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. | Br J Haematol | 2021 | https://conductscience.org/library/papers/33618432 | PubMed |
| 17 | 37019990 | The KMT2A recombinome of acute leukemias in 2023. | Leukemia | 2023 | https://conductscience.org/library/papers/37019990 | PubMed |
| 18 | 28588020 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. | Blood | 2017 | https://conductscience.org/library/papers/28588020 | PubMed |
| 19 | 40332046 | Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. | Blood | 2025 | https://conductscience.org/library/papers/40332046 | PubMed |
| 20 | 39121437 | Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39121437 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42122138 | Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122138 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| KMT2A | 4297 | PubTator's text mining | https://conductscience.org/library/genes/4297 | NCBI Gene |
| MEN1 | 4221 | PubTator's text mining | https://conductscience.org/library/genes/4221 | NCBI Gene |
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41814014
GET https://conductscience.org/api/papers/v1/41814014/authors?page=2